KALY - Kali-Extracts, Inc. Publishes Cannabis Extract Lung Disease Treatment Study Preview
February 05 2019 - 1:52PM
InvestorsHub NewsWire
KALY – Kali-Extracts, Inc.
Publishes Cannabis Extract Lung Disease Treatment Study
Preview
Dallas,
TX – February 5, 2019 -- InvestorsHub NewsWire --
Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today published a preview of the recently announced
long-term, pilot study on the treatment of Chronic Obstructive
Pulmonary Disease (COPD) in primates with cannabis extracts
derived from Kali-Extracts patented cannabis extraction
process. The study adds to the Kali-Extracts in vitro
genomics study, previously announced, to evaluate the impact of its
pharmaceutical grade cannabis extracts in combination with other
therapies on COPD patients. The
World Health Organization estimates 65 million people worldwide are
afflicted with moderate to severe COPD and GlobalData forecasts
that the COPD treatment market will reach $14.1 billion by
2025.
The primate
study was conducted by Professor Jeffry Osbourn, Ph.D., from the
University of Kentucky and his Biomedical Science Research Group (BSRG).
Professor Osbourn made the following statement in regard to the
research: “We investigated the
effects of a novel, new oral-delivered agent for the treatment of
lung diseases like asthma, and inflammation of the lung airways, in
research animals. To our surprise, the new [Kali-Extracts]
supplement increased lung capacity by 2 to 3 times and increased
the rate of breathing, returning lung function to normal.
These large increases in lung function would likely lead to
improved oxygen levels in the blood and increased breathing ability
in these animals. Future experiments are planned to more
closely identify the mechanisms of this improved overall lung
function leading to greatly improved life styles and greater
participation in daily activities for these
patients.”
A final report
on the primate is study coming in March.
Kali-Extracts, Inc. (“KALY”) is a health and
wellness company set to generate revenue from its patented cannabis
extraction technology through overlapping go-to-market
strategies. KALY is utilizing is patented cannabis extraction
process to develop numerous wellness products both internally and
through partnerships. Similarly, KALY its patented cannabis
extraction technology to develop pharmaceutical products internally
and through partnerships.
KALY has
licensed its extraction process to Puration, Inc. (USOTC: PURA)
(“PURA”) for the production of beverages. With over $1
million in trailing twelve-month sales, PURA’s sales of EVERx CBD
Sports Water are growing. KALY is now working with PURA to
formulate a 25 MG CBD formula for a new CBD infused water
product. Together, PURA and KALY have signed over a $1
million agreement to produce CBD infused water for Generex
Biotechnology, Inc. (OTCBB: GNBT). The GNBT product is
expected to be on shelves soon. The PURA and KALY agreement
with GNBT is part of a larger agreement to explore potential
pharmaceutical partnerships.
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024